The Serum Institute of India (SII) on Sunday became the first indigenous company to apply to the Drugs Controller General of India (DCGI) seeking emergency use authorisation (EUA) for the Oxford Covid-19 vaccine in the country, official sources said.
A day earlier, the Indian arm of US pharmaceutical giant Pfizer became the first to seek a similar approval from India’s drug regulator for its Covid-19 vaccine in the country, after securing similar clearances in the UK and Bahrain.
The phase-three clinical trial of the Oxford Covid-19 vaccine–Covishield, is being conducted by the Pune-based Serum Institute of India (SII), co-sponsored by the Indian Council of Medical Research (ICMR), in various parts of the country in addition to clinical studies being carried out by Oxford-AstraZeneca in the UK and Brazil.
Based on phase two and three clinical trial results, the SII with the help of the ICMR will pursue early availability of the vaccine for India, the country’s apex health research body had said last month.
According to the ICMR, the SII has already manufactured 40 million doses of the vaccine under the at-risk manufacturing and stockpiling license it obtained from the DCGI.
Official sources, citing the SII application said, the firm has stated that data from four clinical studies, two in the UK and one each in Brazil and India, shows that Covishield is highly effective against symptomatic and most importantly against severe Covid-19 infections.
The results are in line with other coronavirus vaccines and because of the huge disease burden, Covishield is predicted to alleviate substantial Covid-19 mortality and morbidity, the firm is learnt to have said.
The SII has also submitted 12 batches of the vaccine to the Central Drugs Laboratory (CDL) in Kasauli for testing, a source said.
“In line with our philosophy we assure you that for Covid-19 vaccines also, we are committed to making our country ‘aatmanirbhar’ (self-reliant) and fulfilling our prime minister’s clarion call of ‘vocal for local’ and ‘making in India’ for the world,” stated the application signed by Prakash Kumar Singh, Additional Director, Government and Regulatory Affairs at Serum Institute of India (SII).
In view of all these facts and unmet medical needs in the interest of the public at large to save millions of people in the country and across the globe, early availability of a vaccine against Covid-19 is a necessity, the application further stated.
According to sources, this vaccine is logistically feasible for distribution in the country’s urban and rural regions as it can be stored at two to eight degrees Celsius, which is an ideal temperature for being kept in cold storages in the country.
As a rapid regulatory response, the DCGI on August 2 had given nod to SII for conducting the combined phase two and three human clinical trials of the Oxford Covid-19 vaccine in the country.